Literature DB >> 30848046

Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients.

Adam W Powell1,2, Tarek Alsaied1,2, Omar Niss2,3, Robert J Fleck2,4, Punam Malik2,3,4, Charles T Quinn2,3, Wayne A Mays1,2, Michael D Taylor1,2, Clifford Chin1,2.   

Abstract

PURPOSE: Sickle cell anemia (SCA) patients frequently have many comorbidities, including diastolic dysfunction (DD) and exercise intolerance. SCA patients often cannot reach maximal effort on exercise testing; little is known regarding whether submaximal exercise parameters can predict abnormal maximal exercise results in SCA patients and if there are any possible associations with DD.
METHODS: A prospective longitudinal study was performed in SCA patients. All patients had a resting cardiac MRI (CMR), cardiopulmonary exercise test (CPET) with cycle ergometry using a ramp protocol, and an echocardiogram. Exercise data were compared with age-, gender-, and size-matched normal controls.
RESULTS: Compared with normal controls, the SCA group (n = 19) had lower mean max oxygen consumption (VO2 ; 1378 ± 412 mL/min vs 2237 ± 580, P < 0.01) and workload (117 ± 37.6 watts vs 175 ± 50.5 watts, P = 0.0003). When evaluating the submaximal exercise parameters, there was lower VO2 at the anaerobic threshold (AT; 950 ± 311.7 vs 1460 ± 409.9, P < 0.01) and oxygen uptake efficiency slope (OUES) at AT (1512 ± 426.2 vs 2080 ± 339, P < 0.01). The max VO2 strongly correlated with VO2 at AT (r = 0.9, P < 0.01) and OUES (r = 0.83, P < 0.01) at AT. The VO2 at AT correlated with hematocrit (r = 0.77, P < 0.05). The OUES correlated with left ventricular ejection fraction by CMR (r = 0.55, P = 0.01), hematocrit (r = 0.52, P = 0.02), and lateral E/e' (r = -0.54, P = 0.01).
CONCLUSIONS: SCA patients have abnormal submaximal exercise measures compared with controls, which is strongly associated with abnormal maximal exercise results. The degree of submaximal abnormality correlates with DD abnormalities by echocardiography. These data expand the scope of functional cardiovascular abnormalities in SCA.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiopulmonary exercise test; sickle cell disease; submaximal exercise

Mesh:

Substances:

Year:  2019        PMID: 30848046      PMCID: PMC6472963          DOI: 10.1002/pbc.27703

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  29 in total

1.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.

Authors:  Vandana Sachdev; Roberto F Machado; Yukitaka Shizukuda; Yesoda N Rao; Stanislav Sidenko; Inez Ernst; Marilyn St Peter; Wynona A Coles; Douglas R Rosing; William C Blackwelder; Oswaldo Castro; Gregory J Kato; Mark T Gladwin
Journal:  J Am Coll Cardiol       Date:  2007-01-16       Impact factor: 24.094

2.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  J Am Soc Echocardiogr       Date:  2016-04       Impact factor: 5.251

3.  Hemoglobin concentration and exercise capacity.

Authors:  R D Woodson
Journal:  Am Rev Respir Dis       Date:  1984-02

4.  Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia.

Authors:  Tarek Alsaied; Omar Niss; Adam W Powell; Robert J Fleck; James F Cnota; Clifford Chin; Punam Malik; Charles T Quinn; Michael D Taylor
Journal:  Pediatr Blood Cancer       Date:  2018-05-21       Impact factor: 3.167

5.  Cardiopulmonary Aerobic Fitness Assessment During Maximal and Submaximal Exercise Testing in Pediatric Oncology Patients After Chemotherapy.

Authors:  Adam W Powell; Rajaram Nagarajan; Wayne A Mays; Clifford Chin; Timothy K Knilans; Sandra K Knecht; Michelle A Amos; Yvette M Gerdes; Thomas D Ryan
Journal:  Am J Clin Oncol       Date:  2018-11       Impact factor: 2.339

6.  Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise.

Authors:  R Baba; M Nagashima; M Goto; Y Nagano; M Yokota; N Tauchi; K Nishibata
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

7.  Aerobic parameters of exercise as a function of body size during growth in children.

Authors:  D M Cooper; D Weiler-Ravell; B J Whipp; K Wasserman
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-03

8.  Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.

Authors:  Nihal Bakeer; Jeanne James; Swarnava Roy; Janaka Wansapura; Shiva Kumar Shanmukhappa; John N Lorenz; Hanna Osinska; Kurt Backer; Anne-Cecile Huby; Archana Shrestha; Omar Niss; Robert Fleck; Charles T Quinn; Michael D Taylor; Enkhsaikhan Purevjav; Bruce J Aronow; Jeffrey A Towbin; Punam Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-08       Impact factor: 11.205

9.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

Review 10.  Normal values for cardiovascular magnetic resonance in adults and children.

Authors:  Nadine Kawel-Boehm; Alicia Maceira; Emanuela R Valsangiacomo-Buechel; Jens Vogel-Claussen; Evrim B Turkbey; Rupert Williams; Sven Plein; Michael Tee; John Eng; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2015-04-18       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.